Search clinical trials for: Camrelizumab , apatinib and chemotherapy

Total 4667 results

Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Shanghai Jiao Tong University Affiliated Sixth...

Unknown

A Phase II Study of Apatinib in STS Patients

Soft Tissue Sarcoma
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

ALL, Adult | Philadelphia-Positive ALL | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Italy
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Camrelizumab Utilization on Patients With Advanced Liver Cancer

Advanced Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Fudan University

Unknown

Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

PFS

China
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Masaryk University

Active, not recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF)

Chronic Myeloid Leukemia, Chronic Phase | Withdrawal;Drug

Czechia
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
Fuzhou General Hospital

Recruiting

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Esophageal Squamous Cell Carcinomas

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Treatment of Carrying TP53 Harmful Mutations

Advanced Cancer

China
Shanghai Jiao Tong University School of Medicine

Completed

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Oral Cancer | VEGFR2 Inhibitor | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
Shoucheng Ma

Unknown

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Colorectal Neoplasms

China
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Henan Cancer Hospital

Recruiting

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Advanced Gastric Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Hypopharyngeal Cancer | Immunotherapy | Induction Chemotherapy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

China
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Osteosarcoma

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

Liver Transplantation | Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital

Recruiting

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer (NITDC)

Colon Cancer | Immunotherapy | Mismatch Repair Deficiency

China
PETHEMA Foundation

Completed

Glivec in Ph Positive Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Cromosome Philadelphia Positive

Spain
Fudan University

Not yet recruiting

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Colorectal Cancer

China
Peking Union Medical College Hospital

Completed

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer

China
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Zhejiang Cancer Hospital

Recruiting

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Bladder Cancer

China
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Fudan University

Recruiting

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Not yet recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Primary Hepatocellular Carcinoma
Xijing Hospital

Recruiting

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

ESCC

China
Shanghai Chest Hospital

Unknown

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Recurrence | Metastasis | Esophageal Squamous Cell Carcinoma | Apatinib

China
International Atomic Energy Agency

Completed

Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy

Non Small Cell Lung Cancer

Chile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
yue junhan

Recruiting

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (FOBECAMS)

Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
Sun Yat-sen University

Unknown

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Stage IV Cancer

China
Pfizer

Completed

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States, Ukraine, Poland, Russian Federation, Taiwan, Italy, Spain, United Kingdom, Romania, Switzerland, Japan
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
The Second Affiliated Hospital of Fujian Medical...

Active, not recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Digestive System Diseases | Neoplasms | Neoplasms by Site | Stomach Neoplasms | Digestive System Neoplasms | Stomach Diseases

China

Search clinical trials for: Camrelizumab , apatinib and chemotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations